The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists
https://doi.org/10.17650/1994-4098-2020-16-1-32-36
Abstract
The use of CDK4/6 inhibitors in combination with endocrine therapy (aromatase inhibitors and fulvestrant) allowed us to radically change our understanding of opportunities in the treatment of hormone-positive HER2-negative advanced breast cancer and determine optimal therapy sequencing. The results of randomized clinical trials and over 5-years accumulated international experience in the use of CDK4/6 inhibitors in real clinical practice prove that the use of combinations with CDK4/6 inhibitors can achieve significant efficacy results and increase the survival rates when prescribed in 1 and 2 lines of treatment.
In this paper, we present the results of a survey conducted in July–October 2019 among 48 oncologists in Moscow, that were asked to choose, in their opinion, the most preferable patient’s profile and molecular and biological features of hormone-positive HER2-negative advanced breast cancer, in which the use of combination therapy with CDK4/6 inhibitors will provide the greatest benefit.
Conflict of interest. MD M.A. Mukhina is the medical director of oncology in the Eurasia and Baltic region of Pfizer Innovations Company
About the Authors
L. G. Zhukova
A.S. Loginov Moscow Clinical Scientific Center, Moscow Healthcare Department
Russian Federation
Russian Federation
M. A. Mukhina
Pfizer Innovations
Russian Federation
Russian Federation
References
1. The state of oncological care in Russia in 2019. Eds. A.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow, 2020. (In Russ.).
2. Form No. 7 from 2019, territory: Moscow. (In Russ.).
3. The US Food and Drug Administration. Palbociclib (IBRANCE). Available at: http://https://www.fda.gov/drugs/informationondrugs/approveddrugs/ ucm549978.htm.
4. Sledge G.W.Jr., Toi M., Neven P. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/ HER2– advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35(25):2875–84. DOI: 10.1200/JCO.2017.73.7585.
5. Slamon D.J., Neven P., Chia S. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018;36(24):2465–72. DOI: 10.1200/JCO.2018.78.9909.
6. Turner N.C., Slamon D.J., Ro J. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 2018;379(20):1926–36. DOI: 10.1056/NEJMoa1810527.
7. Im S.-A., Lu Y.-S., Bardia A. et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381(4):307–16. DOI: 10.1056/NEJMoa1903765.
8. Sledge G.W., Toi M., Neven P. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy – MONARCH 2: a randomized clinical trial. JAMA Oncol 2019;6(1):116–24. DOI: 10.1001/jamaoncol.2019.4782.
9. Kish J., Ward M., Garofalo D. et al. Realworld evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one-year post approval. Breast Cancer Res 2018;20(1):37. DOI: 10.1186/s13058-018-0958-2.
10. Varella L., Eziokwu A.S., Jia X. et al. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res Treat 2019;176(2):429–34. DOI: 10.1007/s10549-019-05176-1.
11. Pernas S., Tolaney S.M., Winer E.P., Goel S. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol 2018;10:1758835918786451.
12. Wang L., Gao S., Li D. et al. CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2− breast cancer: a meta-analysis of randomized controlled trials. Breast 2019. DOI: 10.1111/tbj.13703.
Review
For citations:
Zhukova L.G., Mukhina M.A. The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists. Tumors of female reproductive system. 2020;16(1):32-36. (In Russ.) https://doi.org/10.17650/1994-4098-2020-16-1-32-36
Views:
615
Email this article 